Table of Contents 2
List of Tables 5
List of Figures 5
Vertex Pharmaceuticals Incorporated Spshot 6
Vertex Pharmaceuticals Incorporated Overview 6
Key Information 6
Key Facts 6
Vertex Pharmaceuticals Incorporated - Research and Development Overview 7
Key Therapeutic Areas 7
Vertex Pharmaceuticals Incorporated - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combition Treatment Modalities 12
Pipeline Products - Out-Licensed Products 13
Out-Licensed Products/Combition Treatment Modalities 14
Vertex Pharmaceuticals Incorporated - Pipeline Products Glance 15
Vertex Pharmaceuticals Incorporated - Late Stage Pipeline Products 15
Phase III Products/Combition Treatment Modalities 15
Vertex Pharmaceuticals Incorporated - Clinical Stage Pipeline Products 16
Phase II Products/Combition Treatment Modalities 16
Phase I Products/Combition Treatment Modalities 17
Vertex Pharmaceuticals Incorporated - Early Stage Pipeline Products 18
Preclinical Products/Combition Treatment Modalities 18
Discovery Products/Combition Treatment Modalities 19
Vertex Pharmaceuticals Incorporated - Unknown Stage Pipeline Products 20
Unknown Products/Combition Treatment Modalities 20
Vertex Pharmaceuticals Incorporated - Drug Profiles 21
(ivacaftor + tezacaftor) 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
telaprevir 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
VX-150 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
VX-371 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
VX-210 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
VX-970 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
VX-152 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
VX-440 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
VX-803 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
VX-984 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Small Molecule to Inhibit HSP90 alpha/beta for Huntington’s Disease 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
VE-465 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
VE-821 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
VX-241 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
VXC-486 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Small Molecule to Antagonize CGRP Receptor for Migraine 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Small Molecule to Inhibit PI3K Gamma for Undisclosed Indication 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Small Molecules for Multiple Sclerosis 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
VT-12008911 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
P-1055 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Vertex Pharmaceuticals Incorporated - Pipeline Alysis 46
Vertex Pharmaceuticals Incorporated - Pipeline Products by Target 46
Vertex Pharmaceuticals Incorporated - Pipeline Products by Route of Administration 48
Vertex Pharmaceuticals Incorporated - Pipeline Products by Molecule Type 49
Vertex Pharmaceuticals Incorporated - Pipeline Products by Mechanism of Action 50
Vertex Pharmaceuticals Incorporated - Recent Pipeline Updates 52
Vertex Pharmaceuticals Incorporated - Dormant Projects 59
Vertex Pharmaceuticals Incorporated - Discontinued Pipeline Products 60
Discontinued Pipeline Product Profiles 60
ALS-2158 60
telaprevir 60
VX-759 60
VX-983 60
Vertex Pharmaceuticals Incorporated - Company Statement 61
Vertex Pharmaceuticals Incorporated - Locations And Subsidiaries 64
Head Office 64
Other Locations & Subsidiaries 64
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 66
Disclaimer 67